Download MendeleyStructure-based discovery of dual-target inhibitors of the helicase from bagaza virus.
Zhao, R., Shu, W., Hu, W.S., Chen, C., Ning, J.Y., Luo, J., Bai, S.P., Cao, J.M., Zhou, X., Wang, D.P.(2025) Int J Biol Macromol 294: 139536-139536
- PubMed: 39765299
- DOI: https://doi.org/10.1016/j.ijbiomac.2025.139536
- Primary Citation of Related Structures:
8JIX - PubMed Abstract:
Bagaza virus (BAGV) is a mosquito-borne flavivirus and has caused significant avian death in many regions, and also garnered recognition as a significant human pathogen causing diseases like encephalitis. The genome of BAGV encodes ten proteins including three structural proteins and seven nonstructural proteins. The C-terminus of the BAGV NS3 helicase serves as a helicase during BAGV replication, aiding in ATP hydrolysis and unwinding of double-stranded RNA. Here we determined the crystal structure of BAGV helicase and revealed the NTP and RNA binding pockets in the helicase which may be used for exploiting antiviral therapeutics. Using structure-based virtual screening, we discovered 20 compounds targeting both NTP and RNA binding pockets of the helicase. Molecular docking, mutation analysis, isothermal calorimetry (ITC) and the ATPase activity assay demonstrated that epigallocatechin-3-gallate (EGCG), and other top three screened compounds (Quercitrin, Citicoline sodium, Isochlorogenic acid C), showed binding affinities for both the NTP binding site and the RNA binding site of BAGV helicase, and inhibited the ATPase activity of the helicase. Taken together, our discovery of dual-target inhibitors provides a viable strategy for advancing innovative therapies against BAGV, as well as other flaviviruses.
- Department of Cardiology, the First hospital of Shanxi Medical University, and MOE Key Laboratory of Cellular Physiology at Shanxi Medical University, Taiyuan, China.
Organizational Affiliation:
